Literature DB >> 31655458

The elevated systemic cytokine levels in HIV patients are not associated with an elevated pulmonary cytokine environment.

Rafael Fernandez-Botran1, Andrea Reyes Vega2, Yasmany García2, Chanakya Charan Tirumala2, Praneet Srisailam2, Anupama Raghuram2, Paula Peyrani2, Stephen Furmanek2, Mahder Alem Tella2, Jeffrey D Ritzhentaler3, Jesse Roman3, Julio A Ramírez2.   

Abstract

BACKGROUND: HIV-positive patients on anti-retroviral therapy (ART) are at higher risk of developing many non-AIDS related chronic diseases, including chronic obstructive pulmonary disease (COPD), compared to HIV-negative individuals. While the mechanisms are not clear, a persistent pro-inflammatory state appears to be a key contributing factor. The aims of this study were to investigate whether HIV-positive patients without COPD present evidence of potentially predisposing abnormal pulmonary cytokine/chemokine environment and to explore the relationship between pulmonary and systemic cytokine levels.
METHODS: This study included 39 HIV-seropositive and 34 HIV-seronegative subjects without COPD. All were subjected to outpatient bronchoscopy with bronchoalveolar lavage fluid (BALF) aspiration and blood sample collection. The levels of 21 cytokines and chemokines were measured in plasma and BALF using a bead-based multi-analyte assay.
RESULTS: In plasma, HIV-infected patients showed significantly increased circulating levels of pro-inflammatory (TNFα) and Th1-associated cytokines (IL-12p70) as well as several chemokines (CXCL11 and CX3CL1). However, no statistically significant differences were found in the numbers of cells, the concentrations of protein and urea as well as cytokine levels in the BALFs of HIV-positive patients when compared to controls. Correlation analysis indicated a potential modulatory effect of the BMI in HIV-seropositive individuals.
CONCLUSIONS: While our results are consistent with the existence of a systemic pro-inflammatory state in HIV-infected patients, they did not detect significant differences in cytokine levels and other inflammatory markers in the lungs of HIV-positive individuals when compared to HIV-negative controls.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokines; Chronic lung disease (CLD); Cytokines; HIV; Inflammation

Mesh:

Substances:

Year:  2019        PMID: 31655458      PMCID: PMC6938540          DOI: 10.1016/j.cyto.2019.154874

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  29 in total

1.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Authors:  Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay
Journal:  J Infect Dis       Date:  2014-05-01       Impact factor: 5.226

2.  Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.

Authors:  Anne-Sophie Beignon; Kelli McKenna; Mojca Skoberne; Olivier Manches; Ida DaSilva; Daniel G Kavanagh; Marie Larsson; Robert J Gorelick; Jeffrey D Lifson; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

Review 3.  Age-related changes in Type 1 and Type 2 cytokine production in humans.

Authors:  Elizabeth M Gardner; Donna M Murasko
Journal:  Biogerontology       Date:  2002       Impact factor: 4.277

Review 4.  Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.

Authors:  Peter W Hunt; Sulggi A Lee; Mark J Siedner
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

5.  Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.

Authors:  Sumathi Sankaran; Michael D George; Elizabeth Reay; Moraima Guadalupe; Jason Flamm; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

6.  Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.

Authors:  Todd T Brown; Katherine Tassiopoulos; Ronald J Bosch; Cecilia Shikuma; Grace A McComsey
Journal:  Diabetes Care       Date:  2010-07-27       Impact factor: 19.112

7.  Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection.

Authors:  Duy M Dinh; Gretchen E Volpe; Chad Duffalo; Seema Bhalchandra; Albert K Tai; Anne V Kane; Christine A Wanke; Honorine D Ward
Journal:  J Infect Dis       Date:  2014-07-23       Impact factor: 5.226

Review 8.  Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.

Authors:  M Younas; C Psomas; J Reynes; P Corbeau
Journal:  HIV Med       Date:  2015-10-10       Impact factor: 3.180

9.  Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research.

Authors:  Zhenchao Wu; Dong Yang; Zhengwei Ge; Mengdie Yan; Nan Wu; Yi Liu
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

10.  Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis.

Authors:  Yibin Guo; Tianyi Zhang; Zhiyong Wang; Feifei Yu; Qin Xu; Wei Guo; Cheng Wu; Jia He
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more
  2 in total

1.  Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity.

Authors:  Jesper Karlsson; Jonas Wetterö; Maria Weiner; Johan Rönnelid; Rafael Fernandez-Botran; Christopher Sjöwall
Journal:  Arthritis Res Ther       Date:  2022-06-11       Impact factor: 5.606

2.  Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV.

Authors:  Rebekka F Thudium; Hedda Ringheim; Andreas Ronit; Hedda Hoel; Thomas Benfield; Amanda Mocroft; Jan Gerstoft; Marius Trøseid; Álvaro H Borges; Sisse R Ostrowski; Jørgen Vestbo; Susanne D Nielsen
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.